• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴氏病和主动脉扩张中的转化生长因子β-2突变

Transforming Growth Factor Beta-2 Mutations in Barlow's Disease and Aortic Dilatation.

作者信息

Disha Kushtrim, Schulz Solveig, Kuntze Thomas, Girdauskas Evaldas

机构信息

Department of Cardiac Surgery, Central Hospital Bad Berka, Bad Berka, Germany.

Institute of Human Genetics and Anthropology, Jena University Hospital, Jena, Germany.

出版信息

Ann Thorac Surg. 2017 Jul;104(1):e19-e21. doi: 10.1016/j.athoracsur.2017.01.103.

DOI:10.1016/j.athoracsur.2017.01.103
PMID:28633253
Abstract

We report on a patient operated on for degenerative myxomatous mitral and tricuspid valve disease (Barlow's disease) and aortic root dilatation. A valve repair operation and the postoperative course were uneventful. Multigenerational genetic analyses revealed two different mutations in the transforming growth factor beta-2 gene in the same patient. The two mutations in different exons were inherited from both parents each. None of the parents presented with either valve dysfunction or aortic root dilatation. This rare case illustrates potentially common genetic and signaling pathways of concomitant myxomatous valve disease and aortic root dilatation.

摘要

我们报告了一例因退行性黏液瘤样二尖瓣和三尖瓣疾病(巴洛病)以及主动脉根部扩张而接受手术的患者。瓣膜修复手术及术后过程均顺利。多代遗传分析显示,同一患者的转化生长因子β-2基因存在两种不同突变。不同外显子中的这两种突变分别来自父母双方。父母双方均未出现瓣膜功能障碍或主动脉根部扩张。这一罕见病例说明了黏液瘤样瓣膜疾病和主动脉根部扩张可能存在共同的遗传和信号通路。

相似文献

1
Transforming Growth Factor Beta-2 Mutations in Barlow's Disease and Aortic Dilatation.巴氏病和主动脉扩张中的转化生长因子β-2突变
Ann Thorac Surg. 2017 Jul;104(1):e19-e21. doi: 10.1016/j.athoracsur.2017.01.103.
2
Minimally invasive mitral valve repair in Barlow's disease: early and long-term results.巴洛氏病的微创二尖瓣修复术:早期及长期结果
J Thorac Cardiovasc Surg. 2014 Oct;148(4):1379-85. doi: 10.1016/j.jtcvs.2013.11.030. Epub 2014 Jan 10.
3
Barlow's Mitral Valve Disease: A Comparison of Neochordal (Loop) and Edge-To-Edge (Alfieri) Minimally Invasive Repair Techniques.巴洛二尖瓣疾病:新腱索(环)与缘对缘(阿尔菲耶里)微创修复技术的比较
Ann Thorac Surg. 2015 Dec;100(6):2127-33; discussion 2133-5. doi: 10.1016/j.athoracsur.2015.05.097. Epub 2015 Aug 12.
4
Optimal surgical mitral valve repair in Barlow's disease: the concept of functional prolapse.巴洛氏病的最佳二尖瓣手术修复:功能性脱垂的概念
Multimed Man Cardiothorac Surg. 2016 Dec 6;2017. doi: 10.1510/mmcts.2016.001.
5
Echocardiographic measurements alone do not provide accurate non-invasive selection of annuloplasty band size for robotic mitral valve repair.仅靠超声心动图测量并不能为机器人二尖瓣修复术准确无创地选择瓣环成形带的尺寸。
J Heart Valve Dis. 2006 Jul;15(4):524-7; discussion 527.
6
Current Discoveries and Interventions for Barlow's Disease.巴洛氏病的当前研究发现与干预措施
Curr Cardiol Rep. 2016 Aug;18(8):73. doi: 10.1007/s11886-016-0754-5.
7
Prolapse Volume to Prolapse Height Ratio for Differentiating Barlow's Disease From Fibroelastic Deficiency.脱垂容积与脱垂高度比值鉴别巴洛病与纤维弹性缺失。
Circ J. 2017 Oct 25;81(11):1730-1735. doi: 10.1253/circj.CJ-16-1291. Epub 2017 May 31.
8
[W-shaped Resection and Suture of the Posterior Mitral Leaflet in a Patient with Barlow's Disease].[巴洛氏病患者二尖瓣后叶W形切除与缝合术]
Kyobu Geka. 2015 Feb;68(2):90-3.
9
[Simultaneous operation for annulo-aortic ectasia, mitral regurgitation, and tricuspid regurgitation in a patient with Marfan syndrome--report of a case].[马方综合征患者同时行主动脉瓣环扩张、二尖瓣反流和三尖瓣反流手术——病例报告]
Nihon Kyobu Geka Gakkai Zasshi. 1995 Aug;43(8):1223-7.
10
Large annuloplasty rings facilitate mitral valve repair in Barlow's disease.大型瓣环成形环有助于巴洛氏病的二尖瓣修复。
Ann Thorac Surg. 2006 Dec;82(6):2096-100; discussion 2101. doi: 10.1016/j.athoracsur.2006.06.043.

引用本文的文献

1
Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective.靶向转化生长因子-β异构体用于癌症治疗干预的进展与挑战:基于机制的视角
Pharmaceuticals (Basel). 2024 Apr 20;17(4):533. doi: 10.3390/ph17040533.
2
Anti-TGF-β1 aptamer enhances therapeutic effect of tyrosine kinase inhibitor, gefitinib, on non-small cell lung cancer in xenograft model.抗转化生长因子-β1适配体增强酪氨酸激酶抑制剂吉非替尼对异种移植模型中非小细胞肺癌的治疗效果。
Mol Ther Nucleic Acids. 2022 Jun 29;29:969-978. doi: 10.1016/j.omtn.2022.06.001. eCollection 2022 Sep 13.
3
TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism.
转化生长因子β1(TGFβ1)的中和作用通过免疫调节和非免疫肿瘤内在机制发挥治疗效果。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001798.
4
Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression.癌症中 TGF-β 的治疗靶向:破解免疫抑制的主开关。
Clin Sci (Lond). 2021 Jan 15;135(1):35-52. doi: 10.1042/CS20201236.
5
Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.人类与犬黏液瘤样二尖瓣退变的比较病理学:5-羟色胺与转化生长因子-β机制
Cardiovasc Pathol. 2020 May-Jun;46:107196. doi: 10.1016/j.carpath.2019.107196. Epub 2020 Jan 7.
6
A novel TAB2 nonsense mutation (p.S149X) causing autosomal dominant congenital heart defects: a case report of a Chinese family.一个新的 TAB2 无义突变(p.S149X)导致常染色体显性遗传性先天性心脏缺损:一个中国家族的病例报告。
BMC Cardiovasc Disord. 2020 Jan 20;20(1):27. doi: 10.1186/s12872-019-01322-1.